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Abstract
Angiogenesis, the process of new microvessel development, is encountered in a select number of physiological
processes and is central to the pathogenesis of a wide variety of diseases. There is now convincing evidence that
regulated patterns of endothelial cell survival and death, a process known as apoptosis, play a central role in the
periodic remodeling of the vasculature, and in the timely evolution and regression of angiogenic responses. In this
review we discuss the current evidence suggesting a role for inducers and inhibitors of angiogenesis as well as other
mediators that modify endothelial cells functions in the survival and death of endothelial cells. We also discuss how
dysregulation of apoptosis can lead to aberrant angiogenesis as demonstrated in the pathogenesis of retinopathy of
prematurity and cancer.
Introduction
Angiogenesis and apoptosis are biological processes that
are indispensable for normal organ and tissue homeo-
stasis. Programmed cell death, also known as apoptosis,
maintains normal tissue and organ homeostasis by
removing super¯uous, damaged or senescent cells.
Mounting evidence suggests that apoptosis is also
involved in the homeostasis of the vascular system.
Recent studies suggest that endothelial cell apoptosis is
necessary for repair of damaged blood vessels and for
sprouting and branching of capillaries during angiogen-
esis. Events that govern the survival and death of
endothelial cells have emerged as major factors that
contribute to angiogenic responses during embryonic
development, in the maintenance of organ and tissue
homeostasis in adult organisms, and in pathological
conditions such as tumor development. In this review we
will brie¯y summarize the literature on apoptosis and
angiogenesis, and examine more closely the current
knowledge about how the death machinery contributes
to vascular remodeling and angiogenesis. Lastly, we will
show how disruption of the apoptotic program can
contribute to the unrelenting and persistent angiogenesis
that is the hallmark of angiogenesis dependent diseases.
Apoptosis
Programmed cell death is necessary for the development
and survival of multicellular organisms. Every second,
hundreds of thousands of cells are generated in the
human body and a similar number of them die [1]. The
overwhelming majority of these cells die by apoptosis, a
morphologically stereotyped series of cellular events
that result in the deletion of cells without in¯ammation
[2, 3]. The process of programmed cell death was ®rst
described in 1842 in the neuronal system of the develop-
ing toad embryo [4]. However, it was only in 1972 that
the term apoptosis was proposed to de®ne this genet-
ically regulated form of cell death [5]. Programmed cell
death involves expression of genes and protein synthesis,
and is distinguished from necrosis where cell injury and
or in¯ammation results in membrane damage and cell
lysis.
Apoptosis is a key component of a number of
physiological processes. It accounts for the death of
cells necessary for tissue remodeling, for the cell loss that
accompanies atrophy of adult tissues following endo-
crine stimuli, and the removal of cells no longer needed
at the late stages of wound healing [1, 2, 6]. Apoptosis is
the mechanism by which autoreactive lymphocytes are
eliminated during development or after termination
of immune responses [7]. It also eliminates excessive
neutrophils that are produced continuously in the bone
marrow [8, 9].
Apoptosis also maintains organ and tissue homeosta-
sis by eliminating cells that are potentially destructive.
Disruption of the function of a cell caused by viral
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infection generates a signal that induces apoptosis of
infected cells in order to eliminate the virus from the
organism [10]. Perhaps one of the best examples of how
apoptosis guards against intrusion by potentially harm-
ful cell populations is the protective role that this
process plays in the prevention of cancer. Apoptosis
is an ecient mechanism designed to recognize and
eliminate cells that have acquired genetic lesions that are
potentially lethal to the host [7]. In this context, cell
death is a physiologically protective event. In summary,
apoptosis is a mechanism that regulates the reshaping of
tissues and organs, insures the survival of the ®ttest
cells and their optimal adaptation to the environment,
and eliminates infected, damaged, or cells at risk for
neoplastic conversion [1, 7, 11, 12].
Apoptosis is a genetically programmed event
At the cellular level, apoptosis is characterized by a
predictable, well-choreographed series of morphological
and biochemical events. Cells undergoing apoptosis
shrink in volume, detach their neighbors, lose their
microvilli, and detach from one another [2]. The outer
membrane bulges (blebs), the chromatin condenses into
dense granular caps, and the nuclear membrane even-
tually breaks down. At this stage, surface convolution
takes place and the cell is disassembled into a series of
condensed membrane-bound, apoptotic bodies that are
phagocytosed by macrophages or by other adjacent
cells [2].
The events that initiate the apoptotic program are
tightly regulated by an intricate system of controls and
checkpoints that are designed to minimize accidental or
inappropriate activation of the death cascade. Although
it is well recognized that apoptosis plays a central role in
numerous in physiological and pathological processes,
the genetic and biochemical signals that comprise the
cell death machinery are still remain to be de®ned. We
will begin this review with an overview of what is
currently known about the molecular regulation of
apoptosis and the intracellular and extracellular signals
that initiate this cascade.
Initiation and execution of the cell death program
Each cell possesses its own death machinery, which can
be activated on demand. Our understanding of the
molecular events that control apoptosis emerged from
studies in the nematode Caenorhabditis elegans [13, 14].
During development of C. elegans, 1090 cells are
generated of which 131 undergo apoptosis [15]. Genetic
studies in this worm led to the identi®cation and
ordering of key components of the cell death machinery.
The apoptotic program is a highly conserved mechanism
that is mediated by regulators, adaptors, and execution-
ers (eectors) of apoptosis [1, 14]. Figure 1 shows a
comparison of intracellular pathways that control ap-
optosis in nematodes and mammals. In C. elegans,
upstream signals promote the binding of EGL-1
(regulator) protein to CED-9 (regulator) that, in
its turn, releases CED-4 (adapter). Unbound CED-4
induces proteolytic cleavage of CED-3 (executioner) and
a series of downstream events culminating in cell death
[16±19].
In humans, the Bcl-2 family of proteins is composed
of at least 16 members that are critical regulators of
apoptotic pathways and function to either inhibit or to
promote cell death [20±22]. These proteins are located
within the intracellular membranes of mitochondria, the
nucleus, and endoplasmic reticulum and are believed
to form ion-channels/pores when these proteins form
homo and/or heterodimers [22, 23]. The pro-apoptotic
proteins Bad and Bid (human homologues of the
nematode EGL-1) regulate the activity of the antiapop-
totic Bcl-2 and Bcl-xL (homologues of CED-9). Bad and
Bid lack membrane anchoring domains and move from
cytosol to the surface of membranous organelles, where
they can bind to other members of the Bcl-2 family [24].
For example, the dimerization of Bad with Bcl-2
mediates downstream events that result in apoptosis
[22]. Therefore, this step of the apoptotic pathway is
dynamically controlled by the `regulated' translocation
of mobile proteins such as Bid and Bad, and their
binding to anchored proteins such as Bcl-2 and Bcl-xL.
None of the known antiapoptotic Bcl-2 family
members (regulators) interacts directly with caspases
Figure 1. Mechanisms that control cell survival and death in the nematode C. elegans and in mammals. The current understanding of genetic
pathways of apoptosis is described for C. elegans (Top) and mammals (Bottom). Both, the nematode genes and their mammal homologues, are
functionally characterized as regulators, adaptors, or executioners of apoptosis. Symbols: inhibition (a), activation (!). Modi®ed from Vaux and
Korsmeyer [1].
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(executioners) [9, 10]. The function of adaptors (also
called caspase activators) is necessary to transduce pro-
apoptotic signals from regulators to the caspases [25].
For example, Apaf-1 is a human homologue of CED-4
[26] that oligomerizes and activates procaspase-9 when
it is not bound to antiapoptotic proteins of the Bcl-2
family [27, 28]. Therefore, antiapoptotic members of the
Bcl-2 family may inhibit caspa1se activation by pre-
venting oligomerization of the adapter protein Apaf-1
[29±31].
The key executioners of apoptosis are caspases, a
family of cysteine proteases that are normally present in
the cell as proenzymes that require proteolytic cleavage
to become activated [25, 31]. Based on their sites of
action in the apoptotic pathway, these proteases were
divided into upstream caspases (initiator caspases) and
downstream caspases (eector caspases) [31]. In mam-
mals, Apaf-1 is dissociated from pro-survival Bcl-2
family members and activated by dATP and cytosolic
cytochrome c, a protein that is released from the
mitochondria during apoptosis [26, 31, 32]. Upon
activation, Apaf-1 undergoes a conformational change,
which enhances its ability to interact with caspase-9 (an
initiator caspase) through its caspase recruitment do-
main (CARD) [26, 29, 31, 33, 34]. Upon this interaction,
caspase-9 is processed by autocatalysis and subsequently
activates downstream eector caspases such as caspase-3
[25, 33, 35]. When the downstream caspases are acti-
vated, they cleave ICAD (inhibitor of caspase activated
DNAse), allowing CAD (caspase activated DNAse) to
enter the nucleus and degrade chromosomal DNA
[36±38].
A number of cytokines and extracellular proteins
initiate apoptosis by signaling through speci®c cell
membrane receptors [39]. The best characterized death
receptors are CD95 (also known as Fas) and TNFR1
(also termed p55), that belong to the tumor necrosis
factor (TNF) receptor gene superfamily [25, 31, 39].
They have cysteine-rich extracellular domains and a
cytoplasmic sequence termed the `death domain' (DD)
[40, 41]. Binding of the CD95 ligand or TNF to their
respective receptors activates FADD (adapter or
caspase activator) that engages procaspase-8 molecules
in a death-inducing signaling complex (DISC) [42]. The
aggregation of several procaspase-8 molecules mediates
their auto-processing and activation [43, 44]. Active
caspase-8 signals through caspase-3 [45] and triggers
downstream death-inducing events similar to the ones
described above.
Peptides that speci®cally inhibit caspase activity (e.g.
zVAD-FMK, zDEVD-FMK) have been shown to
prevent DNA fragmentation and enhance cell survival
in vitro and in vivo [46±49]. The use of caspase inhib-
itors for treatment of diseases that are caused by
excessive apoptosis is already being evaluated in clinical
trials. However, there are still several unanswered
questions regarding their ecacy and safety for
therapeutic use [50]. Therapeutic strategies designed to
target the recently discovered caspase-independent
pathways of apoptotic death may eventually prove to
be a more reliable and safer alternative to the use of
caspase inhibitors [51±53].
Vasculogenesis and angiogenesis
During the early stages of embryogenesis a primary
vascular plexus develops from endothelial cell precur-
sors or angioblasts by a process termed vasculogenesis
[54, 55]. Subsequently, these cells proliferate and
organize into primitive blood vessels establishing the
initial vascular network. Vascular endothelial growth
factor (VEGF) and its receptors VEGFR-1, VEGFR-2
are important molecules in the initial phase of vascular
development. Knockout mice lacking any one of these
genes die before day 10.5 of embryonic development
by absence or delayed endothelial cell dierentia-
tion and failure of vasculogenesis [56, 57]. After the
primary vascular plexus is formed, endothelial cells
start to proliferate and form new capillaries [55]. The
emerging vascular plexus is rapidly remodeled to
resemble a mature system by a process termed angio-
genesis. This term was ®rst used in 1935 to describe the
formation of new blood vessels from pre-existing
capillaries in the placenta [58]. Recent studies have
demonstrated the presence of endothelial cell precur-
sors in peripheral blood as well as the ability of these
cells to target sites of active angiogenesis [59]. These
®ndings raise the possibility that vasculogenesis and
angiogenesis may not be as distinct from one another
as once thought.
Despite their low turnover (measured in years) in
adult tissues, endothelial cells still retain the capacity
to divide and form new blood vessels in response to
speci®c stimuli [60]. Capillary blood vessels consist of
endothelial cells and pericytes that are programmed to
form a complete capillary network when stimulated by
mediators of angiogenesis [61]. The process of angio-
genesis starts with proteolytic degradation of interstitial
tissue and the basement membrane of the parent vessel.
This is followed by a series of well orchestrated events
in which endothelial cells migrate towards the angio-
genic stimulus and divide [62]. Endothelial cells elon-
gate and align to form a sprout, and the lumen is
formed by a curvature inside each endothelial cell [63].
Individual sprouts elongate and eventually join with
each other forming loops through which blood begins
to ¯ow. Pericytes originating from migrating and de-
dierentiation of arterial smooth muscle cells, position
themselves along the original sprouts and reposition
themselves in the basement membrane that invest newly
formed capillaries [64, 65]. The acquisition of a coating
with pericytes has been recently described as the end of
the `plasticity window' in which the vascular architec-
ture is ®ne tuned according to the availability of
oxygen [66].
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Role of endothelial cell survival and death signals
in angiogenesis
A tightly controlled balance between cell proliferation
and cell death dictates tissue integrity and tissue
homeostasis. Traditionally, regression of neovascular
responses has been associated with inhibition of endo-
thelial cell proliferation, migration, and adhesion [67].
Only recently has the role of endothelial cell survival
and death signals in sustaining and disrupting ne-
ovascularization been recognized. It is now well estab-
lished that key regulators of angiogenesis function, at
least in part, by modulating the survival of endothelial
cells during the processes of vessel repair and angio-
genesis.
For the purposes of discussion we have divided the
regulators of angiogenesis in two broad groups accord-
ing to their role in endothelial cell survival and death:
inducers of endothelial cell apoptosis and enhancers of
endothelial cell survival (Table 1). Many but not all of
these mediators we will describe below have been shown
to function as either antiangiogenic or proangiogenic
factors. When viewed in this context perhaps all
mediators of angiogenesis will eventually be found to
function as either inducers of endothelial cell death or
survival factors.
Inducers of endothelial cell apoptosis
Thrombospondin-1 (TSP1)
TSP1 is the ®rst member of a family of multifunctional
extracellular matrix (ECM) glycoproteins [68±70]. It is
intimately associated with matrix surrounding blood
vessels where it is able to interact with a variety of
growth factors, matrix molecules and cations [71±76].
TSP1 has been implicated in several steps in the
angiogenic response [70, 77±79]. It potently inhibits
endothelial cell proliferation [80±83], migration [82, 84]
and induces vascular disassembly. Endothelial cell
sprouting is enhanced by exposure to anti-TSP1 anti-
bodies [76, 85], and endothelial cells transduced with
antisense TSP1 [82] exhibit an enhanced ability to form
sprout-like structure on arti®cial matrices in vitro.
The potent anti-angiogenic activity of TSP1 has been
localized to two domains within the central stock region
of the molecule: the procollagen homology region
and the properdin-like type I repeats [72, 86±88].
The antiangiogenic eect of TSP1 involves signalling
through the endothelial cell membrane receptor CD36
[89]. Recent data suggest that the antiangiogenic eect
of TSP1 is mediated in part by its ability to induce
endothelial cell apoptosis. TSP1 as well as peptide frag-
ments derived from its antiangiogenic domains have
been shown to induce apoptosis of human umbilical vein
endothelial cells (HUVECs) in vitro [90].
Angiostatin
A 38 kDa internal fragment of plasminogen that
contains the ®rst four disul®de-linked kringle structures
was puri®ed from plasma of mice bearing a Lewis lung
carcinoma, sequenced and named angiostatin [91±93]. It
was characterized as a speci®c inhibitor of endothelial
cell proliferation in vitro and suppressor of tumor
growth and metastatic dissemination in vivo [91, 92,
94]. Angiostatin can be generated by the hydrolysis
of circulating plasminogen by a macrophage-derived
metalloelastase [95], matrilysin and gelatinase B [96], or
stromelysin [97].
The antiangiogenic function of angiostatin is believed
to be mediated, at least in part, by its ability to induce
apoptotic death of endothelial cells [98, 99]. Treatment
of endothelial cells with angiostatin resulted in de-
creased cell numbers without signi®cant eects on DNA
synthesis, suggesting that the decreased proliferation
rates observed in cells exposed to angiostatin were due
to enhanced endothelial cell apoptosis [98, 99]. The
domains responsible for angiostatin pro-apoptotic func-
tion appear to reside in kringle domains 1, 2 and 3 [99].
Tumor necrosis factor
Tumor necrosis factor (TNF) is a multifunctional
cytokine secreted by activated macrophages [100±102]
and T cells [103]. TNF is an important mediator of
in¯ammatory processes and immune responses, where
it was shown to induce tumor regression by hemor-
rhagic necrosis [101, 104]. TNF's function in tumor
Table 1. Classi®cation of regulators of angiogenesis according to their role in endothelial cell survival.
Inducers of endothelial cell apoptosis Enhancers of endothelial cell survival
Thrombospondin-1 (TSP1) Vascular Endothelial Growth Factor (VEGF)
Angiostatin Basic Fibroblast Growth Factor (bFGF)
Tumor Necrosis Factor (TNF) Integrins (aVb3)
Transforming Growth Factor-b (TGF-b) Nitric Oxides (NO)
Lipopolysaccharides (LPS) Estradiol
Amyloid b-peptide Adrenomedullin
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regression has been attributed to its cytotoxic eect on
endothelial cells that results in disruption of the tumor
capillary bed [105]. Several studies have shown that
binding of TNF to endothelial cells results in their
apoptotic death [105±108]. The ability of TNF to
induce endothelial cell apoptosis is enhanced by con-
comitant exposure to inhibitors of protein synthesis
[107±109]. This suggested that TNF might also protect
endothelial cells from apoptosis by utilizing a path-
way(s) that is dependent on protein synthesis [110]. In
fact, TNF was shown to induce expression of the anti-
apoptotic protein A1 (a Bcl-2 homologue) and where
overexpression of A1 was shown to inhibit apoptosis
when endothelial cells were exposed to TNF and
actinomycin D [110]. The recent ®nding that overex-
pression of Bcl-2 further supports this TNF associated
protective mechanism. Bcl-xL also protects endothelial
cells from TNF-mediated apoptosis after sensitization
with cyclohexamide [111].
TNF seems to mediate a multitude of intracellular
signal transduction pathways that are triggered upon its
binding to endothelial cell membrane receptors. These
include activation of: (a) NF-jB, which mediates ex-
pression of IL-8, VEGF, and E-selectin in endothelial
cells [112±115]; (b) Protein kinase C, which leads to the
upregulation of A1 expression and subsequent enhance-
ment of cell survival [110]; (c) Sp1, which mediates
expression of VEGFR-2 [116]; and (d) Ceramides and
c-jun, which result in endothelial cell death [110, 117].
Despite extensive research, the eects of TNF in
endothelial cells are still unclear. While some reports
demonstrate that TNF induces endothelial cell apopto-
sis, other investigations have shown that TNF is
angiogenic [115, 118, 119]. There are a number of
possible explanations for these con¯icting results. (A)
TNF's ability to induce angiogenesis in vivo may be due
to the synthesis of angiogenic factors such as IL-8,
VEGF or bFGF or macrophages [115, 119]. (B)
Responses mediated by TNF are dose-dependent. While
TNF stimulates angiogenesis at low concentrations
[118], it inhibits it in higher concentrations [120]. This
suggests that the induction of endothelial cell death or
survival depends on the expression levels of TNF that
accumulate extracellularly, which in turn determines
whether it transmits a death signal or survival signal to
endothelial cells.
Transforming growth factor-b (TGF-b)
TGF-b has been shown to induce apoptosis of HUVEC
in vitro by downregulating Bcl-2 expression [121]. Choi
and Ballerman have demonstrated that TGF-b induces
apoptosis of renal glomerular endothelial cells and
capillary sprouting in vitro [122]. The authors found
that endothelial cell sprouting is inhibited in dominant
negative mutants if TGF-b type II receptors are
blocked. They concluded that TGF-b-induced endothe-
lial cell apoptosis is necessary for capillary morphogen-
esis [122].
Lipopolysaccharides
Escherichia coli endotoxins (LPS) cause acute pulmo-
nary endothelial cell injury in vivo [123] and endothelial
cell apoptosis in vitro [124]. Recently, a study has
associated LPS with the pathogenesis of endotoxic
shock syndrome that is characterized by generalized
in¯ammation, circulatory collapse and death [125].
Co-injection of LPS with its putative eector (TNF-a)
induces endothelial cell apoptosis that is associated with
enhanced expression of the pro-apoptotic lipid ceramide
[125]. The ability of LPS to induce apoptosis of cultured
sheep pulmonary artery endothelial cells was attenuated
by collagen [124] and by overexpression of the heat
shock protein-70 (HSP-70) [126]. Vitamin C and E have
also been shown to prevent LPS-mediated apoptosis in
HUVEC [127]. The protective eect of these vitamins
was associated with enhanced expression of the anti-
apoptotic protein Bcl-2 and decreased expression of the
pro-apoptotic protein Bax [127].
Other inducers of endothelial cell apoptosis
Several other inducers of endothelial cell apoptosis have
been described in the literature. Interferon-c induces
apoptosis of normal endothelial cells through activation
of the protein kinase C pathway [128]. Amyloid
b-peptide, a molecule involved in neuronal degeneration
observed in the brain of patients with Alzheimer's
disease, has been implicated in the induction of endo-
thelial cell apoptosis [129]. It was suggested that amyloid
b-peptide-induced endothelial cell apoptosis might be
directly involved with the vascular damage frequently
observed in these patients [129]. Cholesterol oxides are
molecules involved in the initiation and progression of
atherosclerosis [130]. Physiological concentrations of
cholesterol oxides induce apoptosis of endothelial cells
and cause damage to the vessel wall [131]. This
observation might explain, at least in part, the role of
cholesterol oxides in the etiology of vascular injury
in vivo [132].
Accutin, a RGD containing small peptide from the
disintegrin family, was recently puri®ed from the viper
venom of Agkistrodon acutus [133]. In vitro, accutin
induces apoptosis of endothelial cells by inhibiting their
adhesion to ®brinogen, ®bronectin, or vitronectin [133].
Furthermore, accutin is anti-angiogenic when evaluated
in the chick chorioallantoic membrane (CAM) assay. It
was suggested that the mechanisms responsible for this
anti-angiogenic eect involve selective blockade of the
endothelial cell integrin aVb3 and consequent induction
of apoptosis [133].
Endothelial cell injury is a component of the `increased
pulmonary edema' that manifests in patients with acute
respiratory distress syndrome (ARDS) [134]. Dawicki
and collaborators showed that extracellular ATP and
adenosine induce apoptosis of pulmonary artery endo-
thelial cells [135]. They speculate that ATP released
from activated platelets and cells undergoing cytolysis in
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ARDS patients causes apoptosis of lung endothelium,
and thereby exacerbates pulmonary injury [135].
Pharmacological agents can also induce endothelial
cell apoptosis. Alkyllyso-phospholipid ET16-Ome, a
putative anti-tumor drug, induces apoptosis when added
to the culture medium of human umbilical vein endo-
thelial cells [136]. Moreover, 2-methoxyestradiol, an
endogenous estrogen metabolite of the oral contracep-
tive 17-ethylestradiol, induces apoptosis of bovine pul-
monary artery endothelial cells in vitro and inhibits
angiogenesis in vivo [137].
Lastly, an important role for accessory cells and
changes in blood ¯ow in endothelial cell apoptosis and
capillary regression has been proposed in a series of
studies by Richard Lang and colleagues [138±142].
During regression of the pupillary membrane, a tran-
sient capillary network found in the anterior chamber of
the developing rodent eye, macrophages initiate apop-
tosis of endothelial cells which leads to capillary
regression. This selective ablation of endothelial cells
results in vessel obstruction and a block in plasma ¯ow
within the clogged capillary segment. Endothelial cells
then die in a `synchronous' manner because they are
deprived of essential survival factors present in plasma.
Recently this group has determined that the major
survival factor in plasma that is responsible for main-
taining the integrity of this embryonic organ is VEGF.
The signi®cance of VEGF as a survival factor will be
discussed in greater detail below.
Enhancers of endothelial cell survival
Vascular endothelial growth factor (VEGF)
In 1983, vascular permeability factor (VPF) was iden-
ti®ed in tumors and characterized as an endothelial
factor that enhances the permeability of microvessels to
circulating molecules [138]. In 1989, two independent
groups reported the cloning and sequencing of an
endothelial cell speci®c mitogen with heparin binding
properties that was called vascular endothelial growth
factor (VEGF) [143±145]. Further sequencing and
characterization led to the conclusion that VPF and
VEGF shared the same biological functions and were
encoded by the same gene. Alternative splicing of VEGF
mRNA originates ®ve human VEGF isoforms, of which
VEGF165 is the predominant molecular species [147,
148]. VEGF has been extensively characterized as a
potent permeability factor [150], endothelial cell speci®c
mitogen and chemoattractant [143, 151] an angiogenic
factor [148, 149], and a mediator of adhesion of natural
killer cells to tumor endothelium by inducing expression
of VCAM-1 and ICAM-1 [152].
More recently, the role of VEGF as an enhancer of
endothelial cell survival has been investigated. VEGF
was shown to protect endothelial cells from apoptosis
induced by TNF by inducing upregulation of b3 integrin
and ®bronectin [153]. It was proposed that the sustained
endothelial cell survival observed in cells exposed to
VEGF was mediated by their enhanced adhesion to
matrix [153, 154]. At approximately the same time,
another group of investigators determined that VEGF
enhanced the survival of microvascular endothelial cells
cultured in hydrophobic polystyrene [155]. Interestingly,
the mechanism suggested for VEGF-induced endothelial
survival in this experimental design was dependent on
vitronectin and a5b5 integrin, not a5b3. The ability to
enhance endothelial cell survival was speci®c to VEGF,
since other angiogenic factors such as bFGF were tested
and did not exhibit the same eect [155].
The mechanisms underlying VEGF's survival func-
tion are starting to be unveiled. VEGF was shown to
upregulate expression of the antiapoptotic protein Bcl-2
and its homologue A1 in endothelial cells in vitro
[156, 157]. Overexpression of Bcl-2 was sucient to
enhance endothelial cell survival and protect against
apoptosis induced by growth factor deprivation [157,
158]. VEGF-mediated Bcl-2 upregulation in endothelial
cells unequivocally potentiates angiogenic responses
in vitro and in vivo [157]. VEGF's survival signal was
shown to be mediated by the Flk-1/KDR receptor and
engagement of the phosphatidylinositol 30-kinase/Akt
transduction pathway [159]. Another group has charac-
terized VEGF's survival function for endothelial cells
cultured in collagen as dependent on the activation of
the mitogen activated protein kinase [MAPK], rather
than the Akt/PKB, signaling pathway [160].
One of the most potent stimuli for VEGF secretion
and angiogenesis is oxygen deprivation. Hypoxia is
associated with a variety of responses at the cellular and
tissue level. Reduced levels of oxygen induce glycolysis
to enhance energy production. It also enhances erythro-
poietin synthesis to increase the oxygen carrying capac-
ity of the blood, and VEGF secretion which enhances
tissue oxygenation by increasing vessel permeability and
promoting neovascularization. An important compo-
nent of the transcriptional response to hypoxia is the
transcription factor HIF-1. This hypoxia-inducible
transcription factor functions by controlling the expres-
sion of a series of target genes that regulate tissue
oxygenation in a number of physiological and patho-
logical settings. Recent work from several laboratories
has established a key role for HIF-1 in the hypoxic
response during embryonic development and angiogen-
esis [161±163]. For example teratocarcinomas derived
from embryonic stem cells null for HIF-1a exhibited a
dramatic reduction in growth and vascularization
[161±163]. This ®nding correlated with a reduced capa-
city of these cells to release VEGF. Furthermore it was
shown that HIF-1a null mutant embryos exhibited a
complete lack of cephalic vascularization, reduced
numbers of somites and abnormal neural fold forma-
tion. Carmeliet and collaborators have reported that
embryonic stem cells null for HIF-1a showed reduced
hypoxia-induced expression of VEGF. This was associ-
ated with a reduction in the formation of large, mature
vessels and impaired vascular function [163].
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The consequences of aberrant expression of HIFa
have been revealed in several recent reports that
examined the molecular basis of unregulated angiogen-
esis in the hereditary cancer syndrome, the von Hippel-
Lindau (VHL) disease [164±166]. Individuals aected by
this disorder develop hemangioblastomas in the retina,
cerebellum and spine as well as the adrenals and kidney.
Interestingly, individuals with this disease exhibit a
molecular and biochemical phenotype reminiscent of
oxygen deprivation. It was recently reported [164] that
the VHL gene binds to the transcription factors HIF-1a
and HIF-2a where it targets them for destruction.
Cells lacking the VHL gene cannot degrade these two
transcription factors. This in turn drives excessive
VEGF synthesis and angiogenesis. Although a number
of questions remain, these recent observations suggest
that VEGF may utilize a number of dierent molecular
pathways to enhance the survival of endothelial cells.
Basic ®broblast growth factor (bFGF)
The FGF family consists of nine structurally related
polypeptides. bFGF was originally puri®ed from the
bovine pituitary gland [167], sequenced, and character-
ized as an angiogenic factor [168]. Araki and colleagues
in 1990 [169] were the ®rst to implicate FGF as a
survival factor for endothelial cells. Enhanced activity
of protein kinase C was associated with the ability of
bFGF to protect endothelial cells against apoptosis
induced by growth factor deprivation [170] or ionizing
radiation in vitro and in vivo [170±172]. In contrast,
tyrosine phosphorylation, but not protein kinase C
activation, was shown to mediate bFGF's protective
eect [173]. The role of bFGF in endothelial cell survival
was further characterized by the ®nding that its removal
from culture medium of murine aortic endothelial cells
was sucient to activate the pro-apoptotic cysteine
protease interleukin-1b-converting enzyme (ICE) and
mediate DNA fragmentation [174]. More, recently, the
anti-apoptotic function of bFGF was associated with its
ability to enhance expression of Bcl-2 [175].
Integrins
Endothelial cells rapidly undergo apoptosis when their
interactions with the extracellular matrix are inhibited,
in a process called `anoikis' [154]. Integrins were
identi®ed as key transducers of extracellular matrix
signals that were required for maintaining cell survival
[154]. There is increasing evidence that integrins also
play a critical role in the regulation of angiogenesis by
modulating endothelial cell survival [176±180]. The
®nding that aVb3 is preferentially expressed in newly
formed microvessels and that monoclonal antibodies to
aVb3 induce endothelial cell apoptosis restricted to these
vessels was immediately considered a major break-
through as a potential anti-angiogenic tumor therapy
[177±180]. The authors hypothesized that if aVb3 liga-
tion is prevented; the endothelial cells will no longer
receive necessary survival signals from the ECM and
undergo apoptosis by default.
The signaling pathways that mediate endothelial cell
survival upon activation of aVb3 have been extensively
studied. Ligation of endothelial cell aVb3 during angio-
genesis promotes a speci®c signal that leads to inhibition
of p53 expression and its inducible partner p21WAF1
(mediator of cell cycle arrest), and suppression of the
pro-apoptotic Bax pathway [181]. The activation of the
transcription factor NF-jB was shown to be dependent
on the GTP-binding protein Ras and the tyrosine kinase
Src, and is necessary for aVb3-mediated endothelial cell
survival [182]. Another study has identi®ed the activa-
tion of the phosphatidylcholine-speci®c phospholipase
C and production of diacylglycerol (DAG) as essential
components of integrin mediated survival signals in
endothelial cells [183].
Exposure of human endothelial cells to gamma
interferon (IFN-gamma) was shown to inhibit the
aVb3-mediated survival pathway and to induce endo-
thelial cell apoptosis in vitro [184]. Treatment of patients
with IFN-gamma also resulted in enhanced endothelial
cell apoptosis in metastatic melanoma [184]. Inactiva-
tion of the integrin pathway during endothelial cell
apoptosis may be due to cleavage of its cytoplasmic
domain. Calpain-mediated proteolysis of the b3 cyto-
plasmic domain was observed during apoptosis of
human umbilical vein endothelial cells, and its inhibition
with sodium orthovanadate (a phosphatase inhibitor)
rescued these cells from apoptosis [180].
Other enhancers of endothelial cell survival
Nitric oxide is a multifunctional molecule that is
synthesized by endothelial cells in low doses through
the activity of the enzyme nitric oxide synthase (eNOS)
[185, 186]. Inhibition of NO was associated with
enhanced endothelial cell apoptosis in con¯uent cultures
of bovine aortic endothelial cells [187]. The authors
suggested that NO has an important role in maintaining
vascular homeostasis and architecture [186].
Enhanced endothelial cell apoptosis has been associ-
ated with the pathogenesis of atherosclerosis [188, 189].
The incidence of coronary disease in post-menopausal
women increases concomitantly with a decrease in the
synthesis of estrogens, and the administration of this
hormone is being considered one of the most eective
anti-atherogenic therapies available for women [190].
Estradiol, a key estrogen metabolite, has been now
characterized as a potent anti-apoptotic mediator for
endothelial cells. Estradiol protected endothelial cells
against apoptosis induced by TNF-a [192]. It was also
shown that estradiol's anti-apoptotic function was
mediated by increased tyrosine phosphorylation of a
focal adhesion kinase that stabilized focal adhesion
contacts [189].
Adrenomedullin, a potent vasorelaxant/hypotensive
peptide, was shown to suppress serum deprivation-
induced apoptosis of rat endothelial cells via a cAMP-
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independent mechanism [192]. Human umbilical vein
and microvascular endothelial cell apoptosis were in-
hibited by physiological concentrations of serum albu-
min [193]. The authors suggested that the removal of
excessive blood vessels in remodeling tissues might be
mediated by a reduced supply of serum albumin to the
endothelial cells.
Lastly, the inhibitor of apoptosis protein family (IAPs)
has received considerable attention over the past 5 years
[194]. Initially discovered in baculoviruses they appear to
be highly conserved across several species including
humans [195, 196]. The IAPs appear to suppress apop-
tosis through direct caspase inhibition (primarily caspase
3 and 7) and by modulation of the transcription factor
NF-jB [197]. Although a role for the IAPs in endothelial
survival and angiogenesis has yet to be established, given
the wide spread distribution of these proteins, it would
not be entirely surprising to ®nd that they play a role in
endothelial cell survival and angiogenesis.
Endothelial cell survival and death signals
in physiological angiogenesis
In response to angiogenic stimuli, endothelial cells
undergo a series of tightly controlled events that result
in sprouting and development of a capillary network
and the remodeling of established vessels. When newly
formed blood vessels are no longer necessary, they
undergo regression. Figure 2 depicts the process of
programmed cell in both angiogenesis and angiosup-
pression. Traditionally, the initiation of angiogenesis has
been described as involving degradation of basement
membrane followed by proliferation and migration of
endothelial cells to form a capillary loop. In 1995, Choy
and Ballermann [122] raised the intriguing possibility
that capillary morphogenesis depended on the selective
apoptosis of endothelial cells mediated by transforming
growth factor-b1 (TGF-b1). This homodymeric poly-
peptide is strongly expressed in sites of tissue morpho-
genesis [198]. It has been shown to induce angiogenesis
in vivo [199] and endothelial cell sprouting in vitro [200].
During the process of capillary morphogenesis, TGF-b1
mediates secretion of plasminogen activator that cleaves
the proenzyme plasminogen and activates plasmin,
which in turn degrades ECM proteins [122]. This results
in detachment and apoptosis of endothelial cells from
selective areas of the developing capillary, and allows for
the initiation of a new capillary loop [122, 201]. Targeted
apoptosis of endothelial cells seem to have an important
physiological role in allowing for the communication
between the newly formed capillary and their `parent'
venules.
Aberrant expression of endothelial cell survival and
death signals characterizes pathological angiogenesis
The role of endothelial cell proliferation and migration
in the pathogenesis of angiogenesis-dependent diseases
and the mediators responsible for aberrant angiogenic
responses have been extensively characterized. More
recently researchers have turned their attention to
characterizing the impact of endothelial survival and
death signals in pathological angiogenesis. The accu-
mulated evidence to date suggests that disruption in the
cell death machinery is central to the pathogenesis of a
number of angiogenesis-dependent diseases (Figure 3).
Two excellent examples of this phenomenon are ret-
inopathy of prematurity, that is caused by excessive
endothelial cell apoptosis in its initial stages [202];
and (b) cancer, that is associated with an unrelenting
Figure 2. Endothelial cell apoptosis in vessel wall remodeling, angiogenesis and angiosuppression. Localized apoptosis of endothelial cells in the
walls of venules is necessary for capillary remodeling. It allows for the communication of lumens of contiguous microvessels during the processes
of sprouting and branching. Apoptosis of endothelial cells is also involved in vascular regression. It is the process by which microvessels are
eliminated in the absence of in¯ammation.
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angiogenic response [203]. These two diseases were
selected for discussion here because there is a consider-
able body of literature about their pathogenesis. How-
ever, it is anticipated that in time new data will emerge
linking changes in the survival pro®le of endothelial cells
to other angiogenesis dependent diseases.
Retinopathy of prematurity
With increasing survival of premature infants weighing
less than 1000 g, the incidence of retinopathy of
prematurity-induced blindness has also increased steadi-
ly [204]. The pathogenesis of retinopathy of prematurity
has been directly associated to the fact that premature
infants are placed in oxygen chambers and exposed to a
hyperoxic environment to provide enough oxygen for
their immature lungs [205]. The exposure of the imma-
ture retina to hyperoxia results in excessive apoptosis of
endothelial cells [67, 206, 208]. When the lungs of the
infant mature, the transition to room air causes exces-
sive retinal neovascularization that is mediated by the
relative ischemia in the retina resulting from the initial
Figure 3. The balance expression of endothelial survival and death signals characterizes physiological angiogenesis. (A) During the initiation
phase of a physiological angiogenic response there is an increase in the level of proangiogenic factors coincidental with a reduction in the level of
angiogenesis inhibitors. This temporary shift to the angiogenic phenotype is accompanied by a transient upregulation in survival signals that is
induced by proangiogenic factors. Also, the number of endothelial cells undergoing apoptosis is reduced due to the diminished level of
angiogenesis inhibitors and/or increased resistance of endothelial cells to the pro-apoptotic eects of angiogenesis inhibitors. Once the metabolic
demands of the tissue have been met, i.e., during the reparative phase of tissue injury, the level of proangiogenic mediators in the tissue decreases
while the level of angiogenesis inhibitors begin to rise. This results in increased endothelial cell apoptosis, and the rapid regression of neovessels.
(B) In angiogenesis dependent diseases the angiogenic phenotype is prolonged resulting in a protracted angiogenic response. The reduction in the
level of angiogenic inhibitors along with a relative or absolute increase in the level of proangiogenic factors results in prolonged upregulation of
endothelial cell survival signals and a marked decrease in endothelial cells undergoing apoptosis. We propose that prolonged upregulation of
survival signals and/or a reducing in death signals contributes to sustained neovascularization that characterizes angiogenesis dependent diseases.
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disruption of blood supply [206, 208±210]. The resulting
aberrant neovascularization is the cause of the severe
ocular disease observed frequently in these infants,
including blindness [211].
The pathogenesis of retinopathy of prematurity has
been extensively studied at the molecular level, and
VEGF is believed to play a major role in this process.
It is known that VEGF is very responsive to subtle
changes in oxygen tension. For example, its expression
levels are increased in hypoxic areas and result in local
induction of neovascularization that re-establishes nor-
mal oxygen supply [145, 212, 213]. Recent reports
demonstrated that VEGF expression is downregulated
soon after the level of oxygen rises in the retina [206,
207, 210, 212], and precedes blood vessel regression
caused by endothelial cell apoptosis [193]. When the
child starts breathing room air, the retina becomes
hypoxic because most blood vessels have been previ-
ously disrupted. In attempt to re-establish normal
oxygen tension to the area, VEGF is upregulated above
physiological levels and causes excessive neovasculariza-
tion that is responsible for the ocular pathology
[206, 207, 210, 212]. This knowledge provides a better
rationale for administrating exogenous VEGF in
infants prior to exposing them to the hyperoxic envi-
ronment of oxygen chambers in an attempt to prevent
endothelial cell apoptosis and maintain the retinal
vasculature [66, 206, 210]. This clinical setting underlines
the important function of VEGF as an angiogenic
mediator and endothelial cell survival factor. It also
demonstrates that this growth factor provides a signal
that is necessary to sustain endothelial cell survival
in vivo and that its premature downregulation results in
the disruption of established as well as newly formed
microvessels.
Cancer
Judah Folkman and colleagues ®rst proposed the
hypothesis that `solid tumors are angiogenesis-depen-
dent' in 1971 [214]. Since then the validity of this
statement has been widely con®rmed [214]. The obser-
vation that tumors grow as `cylinders' and enter into
dormancy unless they acquire a new blood supply
strengthened the concept that tumors were angiogenesis
dependent [215, 216]. A recent study con®rmed this
hypothesis by demonstrating the existence of an inverse
relation between spontaneous apoptosis of tumor cells
and intratumoral microvessel density [217]. The intense
competition for limited oxygen and nutrient supplies, as
well as for physical space inside the mass of a solid
tumor, generates a hostile microenvironment for normal
and neoplastic cells. However, it is clear that tumor cells
have developed mechanisms for enhancing their survival
and enabeling them to grow in nutrient deprived
environments. A question arises with regards to normal
endothelial cells that populate tumor-associated blood
vessels. How do they survive in this hostile environment
and sustain tumor neovascularization?
Tumor-associated endothelial cells receive a contin-
uous input of survival signals from the ECM and
depend on these signals to remain viable and function-
al. These conclusions are supported by the ®ndings
obtained in two elegant experiments from Eli Keshet's
laboratory. VEGF expression was `shut down' with an
inducible VEGF expression system (`Tet-o ') in xeno-
grafted glioma tumors in nude mice. The authors
observed that upon VEGF withdrawal endothelial cells
became apoptotic, tumor neovascularization decreased,
and extensive tumor necrosis took place [202]. In a
second model system, these investigators demonstrated
that castration of SCID mice bearing an androgen-
dependent tumor resulted in decreased intratumoral
expression of VEGF and tumor regression [218]. The
observation that endothelial cells began to undergo
apoptosis before neoplastic cells con®rmed the hypoth-
esis that tumor-associated endothelial cells require
speci®c survival signals mediated by VEGF to remain
viable.
These ®ndings reported above suggest that tumor
regression mediated by withdrawal of VEGF is not due
to inhibition of endothelial cell proliferation. The
turnover of tumor-associated endothelial cells is thought
to occur over several days or weeks. However, in this
study the tumors started to regress after 24 h. Therefore,
the lack of endothelial cell proliferation and migration
cannot be the only mechanism responsible for the
vascular regression observed in these tumors. An alter-
native hypothesis is that VEGF is required for main-
taining endothelial cells survival and to sustain tumor
angiogenesis. When this positive `survival' signal is
eliminated endothelial cells become more responsive to
inhibitors of angiogenesis leading to endothelial cell
apoptosis, vessel disassembly, and tumor regression
(Figure 4).
Conclusions
Angiogenesis is absolutely necessary for embryonic
morphogenesis and for maintaining tissue and organ
homeostasis in adult organisms. Disruption of this
biological process has been unequivocally associated
with several diseases that are now described as being
angiogenesis-dependent. Traditionally, angiogenic me-
diators have been categorized as promoting endothelial
cell proliferation, migration, and adhesion. There is now
compelling evidence that angiogenesis is modulated by a
tightly controlled series of cellular and biochemical
events that determine whether endothelial cells survive
or die. The events that govern the survival and death of
endothelial cells signi®cantly in¯uence the stability and
duration of an angiogenic response. After all, angiogen-
esis would be of little bene®t to developing organisms or
adult tissues undergoing repair if endothelial cells did
not survive and eventually die in a predetermined
manner. Similarly, in pathological settings such as in
neoplasia, tumor cells would be unable to withstand the
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onslaught of nutrient deprivation and physiological
signals designed to cause their demise if endothelial
cells were not able to organize into a microvascular
network. Thus as we look to develop novel strategies
designed to retard pathological angiogenic responses or
enhance physiological angiogenesis, we will have to
consider factors that in¯uence endothelial cell survival
as an integral component of any therapeutic strategy.
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